UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
FORM 4
[ ] Check this box if no longer OMB APROVAL
subject to Section 16. Form 4 or OMB NUMBER: 3235-0287
Form 5 obligations may continue. Expires: September 30, 2000
See Instruction 1(b). Estimated average burden
hours per response........0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935
or Section 30(f) of the Investment Company Act of 1940
(Print or Type Responses)
1. Name and Address of Reporting Person*
Morgan Stanley Dean Witter & Co.(1)
-----------------------------------------------------------------------------
(Last) (First) (Middle)
1585 Broadway
----------------------------------------------------------------------------
(Street)
New York NY 10036
-----------------------------------------------------------------------------
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cardiac Pathway Corporation (CPWY)
-----------------------------------------------------------------------------
3. I.R.S. Identification Number of Reporting Person, if an entity (Voluntary)
-----------------------------------------------------------------------------
4. Statement for Month/Year
12/2000
-----------------------------------------------------------------------------
5. If Amendment, Date of Original (Month/Day/Year)
-----------------------------------------------------------------------------
6. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Director X 10% Owner
--- ---
Officer (give title below) Other (specify below)
--- ---
----------------------------------------------------------------------------
7. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
----
X Form filed by More than One Reporting Person
----
<PAGE>
Table I -- Non-Derivative Securities Acquired, Disposed of or
Beneficially Owned
<TABLE>
1. Title of Security 2. Trans- 3. Trans- 4. Securities Acquired 5. Amount of Securities 6. Ownership 7. Nature of
(Instr. 3) action action (A) or Disposed of Beneficially Owned Form: Direct Indirect
Date Code (D) (Instr. 3, 4 at End of Month (D) or In- Beneficial
(Instr.8) and 5) (Instr. 3 and 4) direct (I) Ownership
(Month/ (Instr. 4) (Instr. 4)
Day/ (A) or
Year) Code V Amount (D) Price
------------------------- --------- ---- --- ------- --- --------- -------------------- -------------- -------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Common Stock 12/20/00 (P) 588,235 A $4.25 588,235 I(2) through
partnerships
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
4(b)(v).
(Over)
SEC 1474 (7-96)
<PAGE>
FORM 4 (continued)
<TABLE>
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of 2. Conversion or 3. Transaction Date 4. Transaction 5. Number of 6. Date Exercisable and
Derivative Exercise Price (Month/Day/Year) Code Derivative Expiration Date
Security of Derivative (Instr. 8) Securities (Month/Day/Year)
(Instr. 3) Security Acquired (A)
or Disposed of
(D) (Instr. 3,
4 and 5)
Date Expiration
Code V (A) (D) Exercisable Date
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Series B Convertaible
Preferred Stock $0.00 Immed. N/A
Series B Convertible
Preferred Stock Warrants $0.00 Immed. 5/31/04
1. Title of 7. Title and Amount of 8. Price of 9. Number of 10. Ownership 11. Nature of
Derivative Underlying Securities Derivative derivative Form of Indirect
Security (Instr. 3 and 4) Security Securities Derivative Beneficial
(Instr. 3) (Instr. 5) Beneficially Security: Ownership
Amount Owned at End Direct (D) (Instr. 4)
or of Month or Indirect
Number (Instr. 4) (I)
of (Instr. 4)
Title Shares
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Series B Convertible
Preferred Stock Common Stock 2,180,000 $1,000.00 10,000 I(2) through
partnerships (3)
Series B Convertaible
Preferred Stock Warrants Common Stock 21,800 $1,000.00 100 I(2) through
partnerships
--------------------------------
Explanation of Responses:
(1) Please see attached Joint Filer Information.
/s/ Peter Vogelsang
(2) The reported securities are owned by Morgan Stanley Venture Partners III, L.P., --------------------------------------------
Morgan Stanley Venture Investors III, L.P. and the Morgan Stanley Venture Partners **Signature of Reporting Person
Entrepreneur Fund, L.P. (collectively, the "Funds"). Morgan Stanley Venture By: Peter Vogelsang, authorized signatory
Capital III, Inc. ("MSVC III, Inc.") is an institutional managing member of for Morgan Stanley Dean Witter & Co.
Morgan Stanley Venture Partners III, L.L.C. ("MSVP III, L.L.C."), the General
Partner of the Funds. MSVC III, Inc. disclaims beneficial ownership of the
securities except to the extent of its pecuniary interests as the institutional
managing member of MSVP III, L.L.C.
/s/ Martin M. Cohen,
(3) 9,900 shares of Series B Convertible Preferred Stock are held by the Funds. --------------------------------------------
The remaining 100 shares of Series B Convertible Preferred Stock is **Signature of Reporting Person
held by Morgan Stanley Dean Witter Equity Funding, Inc. ("MSDWEF, Inc."). By: Martin M. Cohen,
Vice President and Secretary of MSDWEF, Inc.
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. /s/ Debra Abramovitz
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). --------------------------------------------
**Signature of Reporting Person
Note: File three copies of this Form, one of which must be manually signed. By: Debra Abramovitz, Vice President and
space provided is insufficient, see Instruction 6 for procedure. Treasurer of MSVC III, Inc.,
institutional managing member of MSVP
Potential persons who are to respond to the collection of information contained III, L.L.C., the General Partner of the
in this form are not required to respond unless the form displays a currently Funds, for each of these entities.
valid OMB Number.
1/8/01
-------------
Date
Page 2
SEC 1474 (7-96)
</TABLE>
<PAGE>
JOINT FILER INFORMATION
Each of the following joint filers has designated Morgan Stanley Dean
Witter & Co. ("MSDW") as the "Designated Filer" for purposes of the attached
Form 4:
(1) Morgan Stanley Venture Capital III, Inc. ("MSVC III, Inc.")
1221 Avenue of the Americas
New York, New York 10020
(2) Morgan Stanley Venture Partners III, L.L.C. ("MSVP III, L.L.C.")
1221 Avenue of the Americas
New York, New York 10020
(3) Morgan Stanley Venture Partners III, L.P. ("MSVP III, L.P.")
1221 Avenue of the Americas
New York, New York 10020
(4) The Morgan Stanley Venture Partners Entrepreneur Fund, L.P.
(the "Entrepreneur Fund")
1221 Avenue of the Americas
New York, New York 10020
(5) Morgan Stanley Venture Investors III, L.P. ("MSVI III, L.P.")
1221 Avenue of the Americas
New York, New York 10020
(6) Morgan Stanley Dean Witter Equity Funding, Inc. ("MSDWEF,
Inc.")
1221 Avenue of the Americas
New York, New York 10020
Issuer & Ticker Symbol: Cardiac Pathways Corporation (CPWY)
Dates of Events Requiring Statement: 12/20/00
Signature: /s/ Peter Vogelsang
-------------------------------------------------------------
By: Peter Vogelsang, as authorized signatory for MSDW.
Signature: /s/ Debra Abramovitz
-------------------------------------------------------------
By: Debra Abramovitz, as Vice President and Treasurer of
MSVC III, Inc., the institutional managing member of
MSVP III, L.L.C., the General Partner of MSVP III, L.P.,
the Entrepreneur Fund and MSVI III, L.P.
Signature: /s/ Martin M. Cohen
-------------------------------------------------------------
By: Martin M. Cohen, as Vice President and Secretary of
MSDWEF, Inc.
